Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 115 results

Warner-Lambert: the plausibility test for sufficiency of disclosure

UK28-11-2018Sheena Linehan

In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan of Potter Clarkson explores the lessons for patent drafting.

Mexico: new links between patents and pharmaceuticals

Mexico12-11-2018Mariana Gonzalez-Vargas

A new facet of Mexico’s linkage system between patents and pharmaceutical drugs raises several questions that necessitate a careful approach from patent assignees and agents, as Mariana Gonzalez-Vargas of Becerril, Coca & Becerril reports.

Generic competition: when one door closes, another opens

EU, US26-10-2018

With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.

I-MAK: saving lives by curing the patent system

International, US19-10-2018

Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.

SPC waiver: good intentions, but not the right deal?

EU17-10-2018

The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.

USITC: a powerful forum for biologics patent owners

US10-10-2018Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang

Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.

A patent attack on three fronts

India02-10-2018Neeti Wilson, Arpita Kulshreshtha and Gitika Suri

A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.

Two new weapons for defending Hatch-Waxman litigation

US03-09-2018Mark Remus

Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.

SPC export waiver: a long road ahead

EU23-08-2018Trevor Cook

The European Commission’s proposed export waiver for supplementary protection certificates is likely to face opposition and may be delayed by EU parliamentary changes, says Trevor Cook of WilmerHale.

LSIPR 50 2018: Brian Anderson

US22-08-2018

Brian Anderson was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

Showing 1 to 10 of 115 results

LSIPR